Eugene J Koay1, Alexander N Hanania2, William A Hall3, Cullen M Taniguchi4, Neal Rebueno4, Sten Myrehaug5, Katharine L Aitken6, Laura A Dawson7, Christopher H Crane8, Joseph M Herman4, Beth Erickson3. 1. The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ekoay@mdanderson.org. 2. Baylor College of Medicine, Houston, Texas. 3. Medical College of Wisconsin, Milwaukee, Wisconsin. 4. The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. 6. The Royal Marsden, London, England. 7. Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 8. Memorial Sloan Kettering Cancer Center, New York City, New York.
Abstract
PURPOSE: To provide a detailed description of practical approaches to dose escalation in pancreatic cancer. METHODS AND MATERIALS: The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation. RESULTS: A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy. CONCLUSIONS: This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.
PURPOSE: To provide a detailed description of practical approaches to dose escalation in pancreatic cancer. METHODS AND MATERIALS: The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation. RESULTS: A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy. CONCLUSIONS: This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.
Authors: Wensha Yang; Robert Reznik; Benedick A Fraass; Nicholas Nissen; Andrew Hendifar; Ashley Wachsman; Howard Sandler; Richard Tuli Journal: Med Dosim Date: 2014-10-22 Impact factor: 1.482
Authors: Avani D Rao; Ziwei Feng; Eun Ji Shin; Jin He; Kevin M Waters; Stephanie Coquia; Robert DeJong; Lauren M Rosati; Lin Su; Dengwang Li; Juan Jackson; Stephen Clark; Jeffrey Schultz; Danielle Hutchings; Seong-Hun Kim; Ralph H Hruban; Theodore L DeWeese; John Wong; Amol Narang; Joseph M Herman; Kai Ding Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-14 Impact factor: 7.038
Authors: Walid L Shaib; Natalyn Hawk; Richard J Cassidy; Zhengjia Chen; Chao Zhang; Edith Brutcher; David Kooby; Shishir K Maithel; Juan M Sarmiento; Jerome Landry; Bassel F El-Rayes Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-24 Impact factor: 7.038
Authors: James D Murphy; Claudia Christman-Skieller; Jeff Kim; Sonja Dieterich; Daniel T Chang; Albert C Koong Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-14 Impact factor: 7.038
Authors: Chi Lin; Vivek Verma; Quan P Ly; Audrey Lazenby; Aaron Sasson; James K Schwarz; Jane L Meza; Chandrakanth Are; Sicong Li; Shuo Wang; Stephen M Hahn; Jean L Grem Journal: Radiother Oncol Date: 2018-12-20 Impact factor: 6.280
Authors: Devin Schellenberg; Jeff Kim; Claudia Christman-Skieller; Carlene L Chun; Laurie Ann Columbo; James M Ford; George A Fisher; Pamela L Kunz; Jacques Van Dam; Andrew Quon; Terry S Desser; Jeffrey Norton; Annie Hsu; Peter G Maxim; Lei Xing; Karyn A Goodman; Daniel T Chang; Albert C Koong Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-05 Impact factor: 7.038
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Colin S Hill; Lauren Rosati; Hao Wang; Hua-Ling Tsai; Jin He; Amy Hacker-Prietz; Daniel A Laheru; Lei Zheng; Shuchi Sehgal; Vincent Bernard; Dung T Le; Timothy M Pawlik; Matthew J Weiss; Amol K Narang; Joseph M Herman Journal: Pract Radiat Oncol Date: 2022-03-17
Authors: Aaron J Grossberg; Linda C Chu; Christopher R Deig; Eliot K Fishman; William L Hwang; Anirban Maitra; Daniel L Marks; Arnav Mehta; Nima Nabavizadeh; Diane M Simeone; Colin D Weekes; Charles R Thomas Journal: CA Cancer J Clin Date: 2020-07-19 Impact factor: 508.702
Authors: Puneeth Iyengar; Elizabeth Zhang-Velten; Laurence Court; Kenneth Westover; Yulong Yan; Mu-Han Lin; Zhenyu Xiong; Mehul Patel; Douglas Rivera; Joe Chang; Mark Saunders; Anand Shivnani; Andrew Lee; Randall Hughes; David Gerber; Jonathan Dowell; Ang Gao; John Heinzerling; Ying Li; Chul Ahn; Hak Choy; Robert Timmerman Journal: JAMA Oncol Date: 2021-10-01 Impact factor: 33.006
Authors: Richard Simcock; Toms Vengaloor Thomas; Christopher Estes; Andrea R Filippi; Matthew A Katz; Ian J Pereira; Hina Saeed Journal: Clin Transl Radiat Oncol Date: 2020-03-24